These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2137027)

  • 1. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex.
    Schoof DD; Selleck CM; Massaro AF; Jung SE; Eberlein TJ
    Cancer Res; 1990 Feb; 50(4):1138-43. PubMed ID: 2137027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
    Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
    Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS; Whiteside TL; Kanbour A; Herberman RB
    J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
    Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.
    De Jong R; Brouwer M; Rebel VI; Van Seventer GA; Miedema F; Van Lier RA
    Immunology; 1990 Jul; 70(3):357-64. PubMed ID: 2143171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
    Reid I; Lundy J; Donohue JH
    J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes.
    Yagita M; Itoh K; Tsudo M; Schaub LB; Platsoucas CD; Balch CM; Grimm EA
    Cancer Res; 1989 Mar; 49(5):1154-9. PubMed ID: 2783885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
    Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
    J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
    Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
    Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
    Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of MC-38 adenocarcinoma tumor-specific tumor infiltrating lymphocytes by murine anti-CD3 antibody and recombinant interleukin-2.
    Lafreniere R; Borkenhagen K; Bryant LD
    Mol Biother; 1991 Mar; 3(1):26-33. PubMed ID: 1829898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.
    Keller H; Wimmenauer S; Rahner S; Von Kleist S; Farthmann EH
    Anticancer Res; 1996; 16(6B):3565-70. PubMed ID: 9042222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential in vitro activation of CD8-CD4+ and CD4-CD8+ T lymphocytes by combinations of anti-CD2 and anti-CD3 antibodies.
    Yang SY; Rhee S; Welte K; Dupont B
    J Immunol; 1988 Apr; 140(7):2115-20. PubMed ID: 3258328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
    Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
    Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
    Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.